Dr. Stanislaw Burzynski is still practicing medicine in Houston, Texas. Now with nearly six decades in oncology, he continues to see patients at an office located at 9432 Katy Freeway, Suite 200, in Houston. He is listed as accepting new patients, though the scope of what he can offer has narrowed considerably over the years due to regulatory restrictions.
His Current Medical Practice
Burzynski’s Houston office operates under the name Southern Infusion Therapy. While he built his reputation on a proprietary cancer treatment called antineoplastons, the therapy that made him famous (and controversial) is no longer available to new patients. The FDA placed his investigational new drug application under a full clinical hold, meaning the Burzynski Research Institute cannot enroll anyone into clinical trials until that hold is lifted. As of late 2025, it has not been lifted.
What Burzynski offers in his current practice, separate from the research institute, is less clear from public records. His medical license in Texas has a complicated history. In the 1990s, the Texas State Board of Medical Examiners ordered his license suspended, then stayed that suspension and placed him on ten years of probation with conditions including compliance with federal and state drug manufacturing laws and a prohibition on false advertising.
The Burzynski Research Institute’s Financial State
Burzynski isn’t just a physician. He is the president, chairman of the board, and roughly 81% owner of the Burzynski Research Institute, a publicly traded company that files quarterly reports with the SEC. Those filings paint a stark picture. For the nine months ending November 30, 2025, the institute reported a net loss of about $994,000. Its total assets were just $2,265, while its liabilities stood at nearly $70,000. It carried a stockholders’ deficit of over $67,000.
The company itself acknowledged in its filing that these numbers “raise substantial doubt about the Company’s ability to continue as a going concern.” It has generated no significant revenue from external sources since its founding. The institute stays afloat through a research funding agreement in which Burzynski personally funds operations from income generated by his medical practice. That agreement was most recently renewed through February 2026.
Why Antineoplastons Remain Controversial
Burzynski developed antineoplastons in the 1970s, claiming they were peptides and amino acid derivatives that could treat various cancers. He has spent decades conducting clinical trials at his own clinic, publishing case reports and early-phase studies suggesting remissions in some patients. But the core criticism has never changed: no randomized controlled trial of antineoplastons has ever been published in a peer-reviewed scientific journal.
The National Cancer Institute states plainly that antineoplastons are not approved by the FDA for the prevention or treatment of any disease. The NCI also notes that other researchers have been unable to replicate the remissions Burzynski reported, and that some of the apparent treatment effects in brain tumor patients may have been confounded by prior treatments or imaging artifacts. The agency’s summary of evidence on antineoplastons is no longer being updated because there is no new qualifying research to evaluate.
Side effects are not trivial either. The NCI flags serious neurological toxicity as a known risk of antineoplaston therapy.
Decades of Regulatory Battles
Burzynski’s career has been defined as much by legal fights as by medicine. In 1983, the FDA obtained a federal court injunction prohibiting him and his institute from shipping antineoplastons across state lines without FDA approval. That restriction pushed him to frame his treatments as clinical trials, which allowed him to administer the drugs within Texas while seeking the FDA data that could eventually lead to approval. That approval never came.
The Texas medical board’s disciplinary action in the mid-1990s added conditions to his practice, including requirements to comply with drug manufacturing laws, cooperate with board oversight, and notify hospitals where he held privileges about the board’s order. A lower court initially reversed the board’s decision, but an appeals court sided with the board and reinstated the probation terms.
More recently, the FDA’s full clinical hold on his investigational drug application effectively froze the research side of his operation. Without the ability to enroll new trial participants, the institute has no path to generating the phase III trial data that would be needed to move antineoplastons toward approval.
What This Means for Patients Considering Treatment
If you’re searching for Burzynski because you or someone you love has cancer, here is the practical picture. He is physically located in Houston and is listed as accepting patients. But antineoplaston therapy, the treatment most people associate with his name, is not currently available through his clinical trials due to the FDA hold. No version of this therapy has ever been approved for any cancer, and the scientific evidence supporting it remains, in the NCI’s assessment, inconclusive.
The research institute behind the therapy is financially insolvent by its own admission, kept operational only by Burzynski’s personal funding. There is no indication of when or whether the FDA clinical hold will be lifted, and no randomized trial data exists to support the claims that originally drew patients to his clinic.